BIT's 6th Annual International Congress of Antibodies 2014

April 25-28, 2014

We are pleased to announce that Deirdre Sanders, Principal, spoke at BIT's 6th Annual International Congress of Antibodies 2014.  Deirdre presented "Monoclonal Antibodies: Successful and Practical Strategies for Developing and Commercializing Antibody Therapies" in Dalian, China on April 26, 2014.

This session explored the new realities of patenting monoclonal antibody inventions in the United States.  Recent U.S. law on patents, particularly in the areas of patentable subject matter, written description, enablement and obviousness, has led to uncertainty and increasing complexity regarding optimal patent strategies.  The presenter, Deirdre Sanders, provided information and guidance for obtaining monoclonal antibody patents in the United States and maximizing the value of antibody patent portfolios.

Topics discussed in this session included:

  • patenting antibody-related inventions, including compositions, methods of development and manufacture, and methods of treatment;
  • addressing challenges relating to patentable subject matter requirements for biotechnology, in light of the Mayo v. Prometheus and Association of Molecular Pathology vs. Myriad Genetics cases;
  • complying with written description and enablement requirements in light of a number of recent key cases;
  • establishing nonobviousness for antibody patent claims in light of recent post-KSR cases; and
  • developing claim construction strategies to obtain broad and enforceable patent coverage.
     

 For more information, please visit the conference website.

About

April 25-28, 2014

We are pleased to announce that Deirdre Sanders, Principal, spoke at BIT's 6th Annual International Congress of Antibodies 2014.  Deirdre presented "Monoclonal Antibodies: Successful and Practical Strategies for Developing and Commercializing Antibody Therapies" in Dalian, China on April 26, 2014.

This session explored the new realities of patenting monoclonal antibody inventions in the United States.  Recent U.S. law on patents, particularly in the areas of patentable subject matter, written description, enablement and obviousness, has led to uncertainty and increasing complexity regarding optimal patent strategies.  The presenter, Deirdre Sanders, provided information and guidance for obtaining monoclonal antibody patents in the United States and maximizing the value of antibody patent portfolios.

Topics discussed in this session included:

  • patenting antibody-related inventions, including compositions, methods of development and manufacture, and methods of treatment;
  • addressing challenges relating to patentable subject matter requirements for biotechnology, in light of the Mayo v. Prometheus and Association of Molecular Pathology vs. Myriad Genetics cases;
  • complying with written description and enablement requirements in light of a number of recent key cases;
  • establishing nonobviousness for antibody patent claims in light of recent post-KSR cases; and
  • developing claim construction strategies to obtain broad and enforceable patent coverage.
     

 For more information, please visit the conference website.

Back to the Top